Ceftazidime-Decorated Gold Nanoparticles: a Promising Strategy against Clinical Ceftazidime-Avibactam-Resistant Enterobacteriaceae with Different Resistance Mechanisms
- 18 July 2023
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (7) , e0026223
Abstract
Nanoparticle-based antibiotic delivery systems are essential in combating antibiotic-resistant bacterial infections arising from acquired resistance and/or biofilm formation. Here, we report that the ceftazidime-decorated gold nanoparticles (CAZ_Au NPs) can effectively kill clinical ceftazidime-avibactam-resistant Enterobacteriaceae with various resistance mechanisms.Keywords
Funding Information
- Key Laboratory Diagnosis and Translational Research of Zhejiang Province (2022E10022)
This publication has 56 references indexed in Scilit:
- Designing Ecofriendly Bionanocomposite Assembly with Improved Antimicrobial and Potent on-site Zika Virus Vector Larvicidal Activities with its Mode of ActionScientific Reports, 2017
- Formulation of carbapenems loaded gold nanoparticles to combat multi-antibiotic bacterial resistance: In vitro antibacterial studyInternational Journal of Pharmaceutics, 2017
- Drug Metabolism in the LiverClinics in Liver Disease, 2017
- Reengineering Antibiotics to Combat Bacterial Resistance: Click Chemistry [1,2,3]‐Triazole Vancomycin Dimers with Potent Activity against MRSA and VREChemistry – A European Journal, 2016
- The effect of cyclophosphamide on the immune system: implications for clinical cancer therapyCancer Chemotherapy and Pharmacology, 2016
- Colistin-Functionalized Nanoparticles for the Rapid Capture of Acinetobacter baumanniiJournal of Biomedical Nanotechnology, 2016
- Pot economy and one-pot synthesisChemical Science, 2016
- Correlation between antimicrobial resistance and virulence in Klebsiella pneumoniaeEuropean Journal of Clinical Microbiology & Infectious Diseases, 2015
- Pegylated Gold Nanoparticles Induce Apoptosis in Human Chronic Myeloid Leukemia CellsBioMed Research International, 2014
- CMY-42, a Novel Plasmid-Mediated CMY-2 Variant AmpC Beta-LactamaseMicrobial Drug Resistance, 2011